HighGravityDataAmgen — Feb 4, 2025 release
Fiscal 2024 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000318154-25-000005
Showing in the filing
EPS (non-GAAP basis)
“$20.00 to $21.20”
Period
FY2025
Measure
Company-defined measure
Source
Prose
All guidance in this release · 8
Dividend for Q4 FY2024
“$2.25 per share”
Total revenues for FY2025
“$34.3 billion to $35.7 billion”
EPS (GAAP basis) for FY2025
“$10.89 to $12.14”
Tax rate (GAAP basis) for FY2025
“11.0% to 12.5%”
EPS (non-GAAP basis) for FY2025
“$20.00 to $21.20”
Tax rate (non-GAAP basis) for FY2025
“15.0% to 16.0%”
Capital expenditures for FY2025
“approximately $2.3 billion”
Share repurchases for FY2025
“not to exceed $500 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
$Billions, except shares Q4 ’24 Q4 ’23 YOY Δ FY '24 FY '23 YOY Δ Operating Cash Flow $ 4.8 $ 0.5 $ 4.2 $ 11.5 $ 8.5 $ 3.0 Capital Expenditures $ 0.4 $ 0.2 $ 0.1 $ 1.1 $ 1.1 $ 0.0 Free Cash Flow $ 4.4 $ 0.3 $ 4.1 $ 10.4 $ 7.4 $ 3.0 Dividends Paid $ 1.2 $ 1.1 $ 0.1 $ 4.8 $ 4.6 $ 0.3 Share Repurchases $ 0.2 $ — $ 0.2 $ 0.2 $ — $ 0.2 Average Diluted Shares (millions) 542 540 2 541 538 3 Note: Numbers may not add due to rounding $Billions 12/31/24 12/31/23 YTD Δ Cash and Investments $ 12.0 $ 10.9 $ 1.0 Debt Outstanding $ 60.1 $ 64.6 $ (4.5) Note: Numbers may not add due to rounding 2025 Guidance For the full year 2025, the Company expects: • Total revenues in the range of $34.3 billion to $35.7 billion. • On a GAAP basis, EPS in the range of $10.89 to $12.14, and a tax rate in the range of 11.0% to 12.5%. • On a non-GAAP basis, EPS in the range of $20.00 to $21.20, and a tax rate in the range of 15.0% to 16.0%. • Capital expenditures to be approximately $2.3 billion. • Share repurchases not to exceed $500 million. Fourth Quarter Product and Pipeline Update The Company provided the following updates on selected product and pipeline programs: General Medicine MariTide (maridebart cafraglutide, AMG 133) • MariTide is a differentiated peptide-antibody conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes gastric inhibitory polypeptide receptor (GIPR). • In November 2024, data were presented from Part 1 of a Phase 2 chronic weight management study in adults who are living with overweight or obesity, with or without AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Page 11 Type 2 diabetes mellitus. MariTide demonstrated robust weight loss at 52 weeks without a weight loss plateau, significant improvements in cardiometabolic parameters, and is the first obesity treatment with monthly or less frequent dosing to demonstrate safe and effective weight loss in a Phase 2 study. • Part 2 of the Phase 2 chronic weight management study is ongoing in adults who are living with overweight or obesity, with or wi
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.